Your browser doesn't support javascript.
loading
Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli
Zeng, Mei; Xia, Jun; Shi, YI; Ni, Yuxing; Fupin, Hu; Chen, Yijian; Li, Jiabin; Zhang, Jing; Yang, Fan; Li, Xin; Li, Yimin; Wu, Anhua; Wu, Depei; Qiu, Haibo; Wang, Minggui.
Affiliation
  • Qiu, Haibo; Zhongda Hospital. School of Medicine. Department of Critical Care Medicine. Nanjing. CN
  • Wang, Minggui; Fudan University. Key Laboratory of Clinical Pharmacology of Antibiotics. Institute of Antibiotics, Huashan Hospital,. Shanghai. CN
Article in English | BIGG - GRADE guidelines | ID: biblio-1435295
Responsible library: BR1.1
ABSTRACT
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group covering clinical infectious diseases, clinical microbiology, clinical pharmacology, infection control, and guideline methodology experts jointly developed the present clinical practice guidelines based on best available scientific evidence to address the clinical issues regarding laboratory testing, antimicrobial therapy, and prevention of CRGNB infections. This guideline focuses on carbapenem-resistant Enterobacteriales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA). Sixteen clinical questions were proposed from the perspective of current clinical practice and translated into research questions using PICO (population, intervention, comparator, and outcomes) format to collect and synthesize relevant evidence to inform corresponding recommendations. The grading of recommendations, assessment, development and evaluation (GRADE) approach was used to evaluate the quality of evidence, benefit and risk profile of corresponding interventions and formulate recommendations or suggestions. Evidence extracted from systematic reviews and randomized controlled trials (RCTs) was considered preferentially for treatment-related clinical questions. Observational studies, non-controlled studies, and expert opinions were considered as supplementary evidence in the absence of RCTs. The strength of recommendations was classified as strong or conditional (weak). The evidence informing recommendations derives from studies worldwide, while the implementation suggestions combined the Chinese experience. The target audience of this guideline is clinician and related professionals involved in management of infectious diseases.
License
C - Todos os direitos reservados
Subject(s)


Full text: Available Collection: Tematic databases Health context: Sustainable Health Agenda for the Americas / Neglected Diseases / SDG3 - Target 3.3 End transmission of communicable diseases Health problem: Goal 10: Communicable diseases / Zoonoses / Antimicrobial Resistance Database: BIGG - GRADE guidelines Main subject: Drug Resistance, Microbial / Gram-Negative Bacterial Infections Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Observational study Language: English Journal: J Microbiol Inmunol Infect Year: 2023 Document type: Article Institution/Affiliation country: Fudan University/CN / Zhongda Hospital/CN

Full text: Available Collection: Tematic databases Health context: Sustainable Health Agenda for the Americas / Neglected Diseases / SDG3 - Target 3.3 End transmission of communicable diseases Health problem: Goal 10: Communicable diseases / Zoonoses / Antimicrobial Resistance Database: BIGG - GRADE guidelines Main subject: Drug Resistance, Microbial / Gram-Negative Bacterial Infections Type of study: Controlled clinical trial / Diagnostic study / Practice guideline / Observational study Language: English Journal: J Microbiol Inmunol Infect Year: 2023 Document type: Article Institution/Affiliation country: Fudan University/CN / Zhongda Hospital/CN
...